亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

蘇州全輝生物科技有限公司  

醫藥原料及中間體生產銷售

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:劉才伙
  • 電話:0512-66368265
  • 郵件:contact@szqhbio.com
  • 傳真:0512-66368287
  • QQ:1259679610
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > ***美托咪啶
***美托咪啶
單價 面議對比
詢價 暫無
發貨 江蘇蘇州市付款后3天內
過期 長期有效
更新 2016-02-17 09:26
 
詳細信息
 

***美托咪啶

產品名稱:***美托咪啶

英文名稱:Medetomidine Hcl

化學名稱:(R)-4-[1-(2,3-二甲基苯基)乙基]-1H-咪唑***

英文化學名:(R)-4-[1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole hydrochloride

分子式:C13H16N2•HCL

分子量:236.74

CAS號:86347-15-1

質量標準:企業標準

性狀:白色或類白色結晶性粉末

熾灼殘渣:不得過0.1%

干燥失重:不得過0.5%

有關物質:單個雜質不得過0.5%;總雜質不得過1.0%

含量:不得少于99.0%

包裝:1kg,5kg,10kg;鋁箔袋/紙板桶/按客戶要求包裝

聯系方式:銷售陳:0512-66368265;18994391946QQ1259679610;contact@szqhbio.*

©2025 蘇州全輝生物科技有限公司 版權所有   技術支持:化工網   訪問量:4709  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |